Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AbGn-168H for Steroid Refractory aGVHD
NCT02436460Phase 1Terminated
- Sponsor
- AbGenomics
- Start
- May 2015
- Primary completion
- Mar 2016
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of neihulizumab in Acute Graft-Versus-Host Disease (aGvHD), sponsored by AbGenomics. Primary endpoints: Adverse events, Cytokine release syndrome or acute infusion reactions and 2 more. Started May 2015; status: terminated.
02
Drugs
neihulizumab
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NCT02436460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02436460.